The Microvascular Imaging Super Resolution Contrast-Enhanced Ultrasound application reportedly leverages micro-bubble contrast media to provide enhanced spatial resolution for imaging of malignant lesions.
Providing an alternative to the use of IV iodinated contrast media for assessing blood flow to and from malignant lesions, Philips has launched the Microvascular Imaging Super Resolution Contrast-Enhanced Ultrasound (CEUS) application, which was recently showcased at the International Bubble Conference in Chicago.
Recognizing that iodinated contrast media can lead to tolerability issues for some patients, Philips noted the new CEUS application, available on the Philips EPIQ Elite ultrasound device, utilizes micro-bubble contrast media derived from an inert gas excreted during breathing. The technology offers significantly improved spatial resolution, according to Philips.
Dirk-André Clevert, M.D, said the microvascular imaging capabilities of the new CEUS application elevate clinician assessment of lesions.
“Philips’ microvascular imaging allows us to visualize the pattern of contrast media flow into a lesion, and also shows how it changes over time, which gives us greater diagnostic confidence in assessing indeterminate lesions,” said Dr. Clevert, a professor of radiology at Ludwig-Maximilians-Universität (LMU) in Munich, Germany.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Multicenter Study Shows Merits of AI-Powered Ultrasound Assessment for Detecting Ovarian Cancer
January 3rd 2025Adjunctive AI offered greater than seven percent increases in sensitivity, specificity, and accuracy for ultrasound detection of ovarian cancer in comparison to unassisted clinicians who lacked ultrasound expertise, according to findings from new international multicenter research.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.